Streetbeat News

ACHV

Achieve Life Sciences, Inc.

https://www.achievelifesciences.com

Industry

Biotechnology

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Open

4.23

Mkt cap

152M

Volume

80K

High

4.45

P/E Ratio

-3.95

52-wk high

5.98

Low

4.23

Div yield

N/A

52-wk low

3.03

Achieve Life Sciences will present data from its Cytisinicline ORCA-V1 program at the SGIM Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

May 17, 2024 | 12:01 pm

Oppenheimer analyst Francois Brisebois maintains an Outperform rating on Achieve Life Sciences (ACHV) but lowers the price target from $18 to $11.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 12:29 pm

Achieve Life Sciences reported Q1 2024 GAAP EPS of $(0.26), missing the $(0.24) estimate by 8.33%. This represents a 48% improvement over the $(0.50) per share loss from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 9:10 pm

Achieve Life Sciences has filed a prospectus with the SEC for the potential offer and sale of up to 13.1 million shares of common stock by selling stockholders. This move could impact the company's stock liquidity and potentially dilute current shareholders' equity.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 8:40 pm

JonesTrading analyst Justin Walsh has initiated coverage on Achieve Life Sciences (NASDAQ:ACHV) with a Buy rating and set a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 2:14 pm

Oppenheimer analyst Francois Brisebois reiterates an Outperform rating on Achieve Life Sciences (NASDAQ:ACHV) and maintains an $18 price target.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 1:14 pm

Achieve Life Sciences (NASDAQ:ACHV) reported Q4 earnings, beating estimated earnings by 16.0% with an EPS of $-0.26 versus an estimate of $-0.31. However, revenue was unchanged from the same period last year. In the previous quarter, the company also beat EPS estimates which was followed by a 2.0% drop in share price the next day.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 8:15 pm

Achieve Life Sciences reported Q4 earnings with losses of $(0.26) per share, surpassing the analyst consensus estimate of $(0.31) by 16.13%. This marks a significant improvement from the $(0.83) per share loss reported in the same quarter last year.

Portfolio Pulse from dijoy@benzinga.com

March 28, 2024 | 8:14 pm

Earnings reports for March 28, 2024, include a mix of expected profits and losses across various sectors. Notable companies like Walgreens Boots Alliance and MSC Industrial Direct Co anticipate earnings, while others like Shimmick and Affimed project losses. The diversity of industries, from healthcare to technology and finance, highlights the varied performance within the market.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 9:24 am

Achieve Life Sciences (NASDAQ:ACHV) is expected to report a Q4 earnings per share (EPS) of $-0.31 on March 28, 2024. Analysts and investors will be looking for an earnings beat and positive guidance for future growth. The company's past earnings performance shows a mix of beats and misses, with the share price reacting variably. Currently, shares are trading at $4.66, down 27.85% over the last 52 weeks, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 3:02 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.